SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Dyadic

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Paul Lee2/29/2012 9:42:53 AM
   of 9
 
DYADIC INTERNATIONAL PARTNERS WITH LEADING PROVIDER OF NUTRITIONAL INGREDIENT SOLUTIONS FOR PRODUCTION OF FOOD ENZYMES



JUPITER, Fla., February 29, 2012 - Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that it has entered into a research, development and license agreement with a leading global provider of nutritional ingredient solutions to use Dyadic’s patented and proprietary C1 platform technology to develop, manufacture and commercialize key enzyme products for food applications.



Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “We are very fortunate to partner with a company that has such a long history of providing innovative and effective products. Dyadic looks forward to utilizing its C1 technology for the expression of next generation enzyme products for food applications. This collaboration is yet another example of Dyadic’s ability to continue leveraging its technologies in a variety of industries by providing its partners with the pathway towards greater profitability through better performing products at lower costs and higher yields.”



Under this agreement, Dyadic’s partner will fund research at Dyadic’s research and development center in the Netherlands to develop customized C1 fungal strains that can produce high levels of key enzymes for food applications. Dyadic has granted its partner a worldwide license to use these developed C1 fungal strains to manufacture and sell these key ingredients used in manufacturing certain foods.



In addition to research funding, if the research is successful and Dyadic’s partner commercializes enzyme products derived from Dyadic’s C1 technology, Dyadic will be eligible to receive commercial milestone payments as well as ongoing royalties based on the production of these enzyme products. Additionally, if Dyadic is successful in achieving the desired enzyme yields in this project, both parties agree that it will lead to collaboration on additional development projects for the food industry.



At the request of Dyadic’s partner, Dyadic has agreed to keep the identity of its partner confidential until further notice.



About Dyadic



Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext